Surmodics Pronounces SWING Trial 12-Month Knowledge To Be Introduced At VEITHsymposium On November 16
Surmodics, Inc. (NASDAQ:SRDX), a number one supplier of medical machine and in vitro diagnostic applied sciences to the well being care trade, introduced at the moment that Professor Ramon Varcoe will current 12-month knowledge from the SWING Trial, a first-in-human research of the security and efficacy of the Sundance™ Sirolimus Drug-Coated Balloon (DCB). The session will likely be held on Wednesday, November 16, on the 49th Annual Symposium on Vascular and Endovascular Points (VEITHsymposium) in New York Metropolis.
SESSION TITLE: The SWING Trial: First-in-Human Use of a Sirolimus DCB in Arteries Under-the-Knee
DATE: Wednesday, November 16
TIME: 9:24 – 9:29 AM (EST); 8:24 – 8:29 AM (CST)
VENUE: New York Hilton Midtown – Grand Ballroom East, third Flooring
Professor Varcoe, MBBS, MS, FRACS, PHD, MMed (ClinEpi), co-lead investigator of the SWING Trial, is a vascular surgeon at Sydney’s Prince of Wales and Prince of Wales Hospital the place he’s Director of Working Theatres, and Director of Surgical procedure and Anesthetics for the South East Sydney Well being District. He’ll evaluation security and efficacy knowledge collected via 12 months of follow-up for 35 topics with occlusive illness of the infra-popliteal arteries who have been handled at research websites in Australia, New Zealand, and places in Europe. Examine topics will likely be adopted for 36 months after the index process. Professor Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, Director of Northern Area Interventional Radiology Service at Auckland Metropolis Hospital in Auckland, New Zealand, can be a co-lead investigator for the SWING Trial.
Professor Varcoe lately introduced SWING Trial 6-month knowledge on October 11 as a part of the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
The Sundance Sirolimus Drug-Coated Balloon makes use of a next-generation coating know-how consisting of microcrystalline sirolimus and a proprietary excipient designed to maximise drug switch, enhancing sirolimus supply and sustaining therapeutic ranges within the artery. Sirolimus, a potent anti-inflammatory and anti-proliferative compound, has been used efficiently in coronary drug-eluting stents. The supply of sirolimus to the vessel wall throughout mechanical balloon dilatation supplies an ancillary motion of inhibiting the proliferation of cells, with the meant objective of decreasing restenosis. The Sundance Sirolimus Drug-Coated Balloon just isn’t obtainable on the market wherever on the planet, and at the moment is for investigational use solely.
